Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Lung Cancer

Free Subscription 24.05.2021 2 AJR Am J Roentgenol 2 Am J Clin Oncol 2 Ann Surg Oncol 1 Anticancer Res 1 Arch Bronconeumol 5 BMC Cancer 3 Br J Cancer 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Lett 3 Cancer Res 3 Clin Nucl Med 1 Eur J Cardiothorac Surg 1 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 1 J Nucl Med 1 J Thorac Cardiovasc Surg 1 JAMA Oncol 2 Lancet Oncol 6 Lung Cancer 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. BRUZZI JF
   Editorial Comment: Metabolic Tumor Volume on FDG PET/CT for Predicting Lymphovascular Invasion of Lung Cancer-Proceed With Caution.
   AJR Am J Roentgenol. 2021 May 19. doi: 10.2214/AJR.21.26193.
   PubMed        
   
   
2. KOO CW
   Editorial Comment: Lobectomy Versus Sublobar Resection-How Preoperative CT Features Can Tell You How Much to Resect in Stage IA Non-Small Cell Lung Cancer.
   AJR Am J Roentgenol. 2021 May 19. doi: 10.2214/AJR.21.26175.
   PubMed        
   
   

   
   Am J Clin Oncol

3. ROH J, Eom JS, Lee MK, Kim J, et al
   Prognostic Factors of Second-line Immune Checkpoint Inhibitors in Patients With Advanced-stage Non-Small Cell Lung Cancer: A Multicenter, Retrospective Study.
   Am J Clin Oncol. 2021 May 17. pii: 00000421-900000000-98562.
   PubMed         Abstract available
   
   
4. TUMINELLO S, Petralia F, Veluswamy R, Wang P, et al
   Prognostic Value of the Tumor Immune Microenvironment for Early-stage, Non-Small Cell Lung Cancer.
   Am J Clin Oncol. 2021 May 19. pii: 00000421-900000000-98563.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

5. WEI X, Yu H, Shi Q
   ASO Author Reflections: Using Patient-Reported Outcomes to Evaluate Surgical Approaches for Locally Advanced Lung Cancer.
   Ann Surg Oncol. 2021 May 15. pii: 10.1245/s10434-021-10018.
   PubMed        
   
   
6. NAKAMURA A, Kondo N, Nakamichi T, Hashimoto M, et al
   Complications and Predictive Factors for Air Leak > 10 Days with Neoadjuvant Chemotherapy Followed by Pleurectomy/Decortication for Malignant Pleural Mesothelioma.
   Ann Surg Oncol. 2021;28:3057-3065.
   PubMed         Abstract available
   
   

   
   Anticancer Res

7. SHIROSHITA A, Kurosaki M, Takeshita M, Kataoka Y, et al
   Medical Thoracoscopy, Computed Tomography-guided Biopsy, and Ultrasound-guided Biopsy for Malignant Pleural Mesothelioma: A Systematic Review.
   Anticancer Res. 2021;41:2217-2225.
   PubMed         Abstract available
   
   

   
   Arch Bronconeumol

8. DE-TORRES JP, Wisnivesky JP
   Lung Cancer Screening in Patients With Chronic Obstructive Pulmonary Disease: Do the Benefits Outweigh the Risks?
   Arch Bronconeumol. 2021 Apr 26. pii: S0300-2896(21)00141.
   PubMed        
   
   

   
   BMC Cancer

9. ZHU D, Ding R, Ma Y, Chen Z, et al
   Comorbidity in lung cancer patients and its association with hospital readmission and fatality in China.
   BMC Cancer. 2021;21:557.
   PubMed         Abstract available
   
   
10. STORK T, Boemans R, Hardes J, Streitburger A, et al
    Number of metastases and their response to chemotherapy impact survival of patients with isolated lung metastases from bone-derived sarcoma.
    BMC Cancer. 2021;21:375.
    PubMed         Abstract available
    
    
11. ZHU D, Cao D, Shen M, Lv J, et al
    Morphological and genetic heterogeneity of synchronous multifocal lung adenocarcinoma in a Chinese cohort.
    BMC Cancer. 2021;21:176.
    PubMed         Abstract available
    
    
12. JARRY U, Bostoen M, Pineau R, Chaillot L, et al
    Correction to: Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment.
    BMC Cancer. 2021;21:574.
    PubMed        
    
    
13. GO SI, Park MJ, Lee GW
    Clinical significance of the cachexia index in patients with small cell lung cancer.
    BMC Cancer. 2021;21:563.
    PubMed         Abstract available
    
    

    
    Br J Cancer

14. GELSOMINO F, Tiseo M, Barbieri F, Riccardi F, et al
    Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
    Br J Cancer. 2021 May 19. pii: 10.1038/s41416-021-01439.
    PubMed        
    
    
15. CHENG Y, Wang Q, Li K, Shi J, et al
    Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study.
    Br J Cancer. 2021 May 18. pii: 10.1038/s41416-021-01356.
    PubMed         Abstract available
    
    
16. ROBBINS HA, Alcala K, Swerdlow AJ, Schoemaker MJ, et al
    Correction: Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom.
    Br J Cancer. 2021 May 17. pii: 10.1038/s41416-021-01436.
    PubMed        
    
    

    
    Cancer Epidemiol Biomarkers Prev

17. DEROUEN MC, Thompson CA, Canchola AJ, Jin A, et al
    Integrating electronic health record, cancer registry, and geospatial data to study lung cancer in Asian American, Native Hawaiian and Pacific Islander ethnic groups.
    Cancer Epidemiol Biomarkers Prev. 2021 May 17. pii: 1055-9965.EPI-21-0019.
    PubMed         Abstract available
    
    

    
    Cancer Lett

18. ZHANG H, Jiang H, Zhu L, Li J, et al
    Cancer-associated fibroblasts in non-small cell lung cancer: Recent advances and future perspectives.
    Cancer Lett. 2021 May 18. pii: S0304-3835(21)00224.
    PubMed         Abstract available
    
    

    
    Cancer Res

19. KONEN JM, Rodriguez BL, Padhye A, Ochieng JK, et al
    Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC.
    Cancer Res. 2021;81:1398-1412.
    PubMed         Abstract available
    
    
20. DENEKA AY, Kopp MC, Nikonova AS, Gaponova AV, et al
    Nedd9 restrains autophagy to limit growth of early stage non-small cell lung cancer.
    Cancer Res. 2021 May 18. pii: 0008-5472.CAN-20-3626.
    PubMed         Abstract available
    
    
21. DAI M, Boudreault J, Wang N, Poulet S, et al
    Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair Pathways.
    Cancer Res. 2021;81:1332-1346.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

22. ARSLAN E, Erol O, Beyhan E, Sahin R, et al
    Detection of Cauda Equine Syndrome With 18F-FDG PET/CT and Leptomeningeal Metastasis by 68Ga-DOTATATE in the Same Patient With Large Cell Neuroendocrine Carcinoma of Lung.
    Clin Nucl Med. 2021 Mar 4. pii: 00003072-900000000-96171.
    PubMed         Abstract available
    
    
23. MASSA F, Filippi L, Benedetti L, Morbelli S, et al
    FDG PET Unveils the Course of Paraneoplastic Cerebellar Degeneration: A Semiquantitative Analysis.
    Clin Nucl Med. 2021 Feb 20. pii: 00003072-900000000-96198.
    PubMed         Abstract available
    
    
24. VERCOSA AFA, Mota IA, Flamini MEDM, Flamini RC, et al
    Paraneoplastic Limbic Encephalitis Secondary to SCLC on 18F-FDG PET/CT.
    Clin Nucl Med. 2021;46:494-496.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

25. WALLER DA, Opitz I, Bueno R, Van Schil P, et al
    Divided by an ocean of water but united in an ocean of uncertainty: a transatlantic review of mesothelioma surgery guidelines.
    Eur J Cardiothorac Surg. 2021;59:8-11.
    PubMed        
    
    

    
    Int J Radiat Oncol Biol Phys

26. QIU B, Li Q, Liu J, Huang Y, et al
    Moderately Hypofractionated Once-daily Compared with Twice-daily Thoracic Radiotherapy Concurrently with Etoposide and Cisplatin in Limited-stage Small-cell Lung Cancer: a Multi-center, Phase II, Randomized Trial.
    Int J Radiat Oncol Biol Phys. 2021 May 13. pii: S0360-3016(21)00490.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

27. ZHAO Y, Liu Y, Li S, Peng Z, et al
    Role of lung and gut microbiota on lung cancer pathogenesis.
    J Cancer Res Clin Oncol. 2021 May 20. pii: 10.1007/s00432-021-03644.
    PubMed         Abstract available
    
    

    
    J Nucl Med

28. GUBERINA M, Poettgen C, Metzenmacher M, Wiesweg M, et al
    PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.
    J Nucl Med. 2021 May 20. pii: jnumed.120.260646. doi: 10.2967/jnumed.120.260646.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

29. BONNER SN, Wakeam E
    The volume-outcome relationship in lung cancer surgery: The impact of the social determinants of health care delivery.
    J Thorac Cardiovasc Surg. 2021 Apr 20. pii: S0022-5223(21)00593.
    PubMed        
    
    

    
    JAMA Oncol

30. CORBETT K, Sharma A, Pond GR, Brastianos PK, et al
    Central Nervous System-Specific Outcomes of Phase 3 Randomized Clinical Trials in Patients With Advanced Breast Cancer, Lung Cancer, and Melanoma.
    JAMA Oncol. 2021 May 20. pii: 2780060. doi: 10.1001/jamaoncol.2021.1359.
    PubMed        
    
    

    
    Lancet Oncol

31. SEPESI B, Cascone T
    Will radiotherapy be a future part of neoadjuvant therapy in operable non-small-cell lung cancer?
    Lancet Oncol. 2021 May 17. pii: S1470-2045(21)00261.
    PubMed        
    
    
32. ALTORKI NK, McGraw TE, Borczuk AC, Saxena A, et al
    Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.
    Lancet Oncol. 2021 May 17. pii: S1470-2045(21)00149.
    PubMed         Abstract available
    
    

    
    Lung Cancer

33. PROVENCIO M, Mazarico Gallego JM, Calles A, Antonanzas M, et al
    Lung cancer patients with COVID-19 in Spain: GRAVID study.
    Lung Cancer. 2021 May 14. pii: S0169-5002(21)00193.
    PubMed         Abstract available
    
    
34. WISLEZ M, Domblides C, Greillier L, Mazieres J, et al
    Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA).
    Lung Cancer. 2021 May 13. pii: S0169-5002(21)00192.
    PubMed         Abstract available
    
    
35. PILLERON S, Maringe C, Charvat H, Atkinson J, et al
    Age disparities in lung cancer survival in New Zealand: The role of patient and clinical factors.
    Lung Cancer. 2021 May 13. pii: S0169-5002(21)00194.
    PubMed         Abstract available
    
    
36. ROGASCH JMM, Frost N, Bluemel S, Michaels L, et al
    FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow.
    Lung Cancer. 2021 May 7. pii: S0169-5002(21)00171.
    PubMed         Abstract available
    
    
37. NEWMAN NB, Osmundson EC
    Practical demonstration of time bias with administration of adjuvant therapy in lung cancer.
    Lung Cancer. 2021 Apr 26. pii: S0169-5002(21)00161.
    PubMed         Abstract available
    
    
38. DUVERGE L, Bondiau PY, Claude L, Supiot S, et al
    Discontinuous stereotactic body radiotherapy schedule increases overall survival in early-stage non-small cell lung cancer.
    Lung Cancer. 2021 May 15. pii: S0169-5002(21)00195.
    PubMed         Abstract available
    
    

    
    PLoS One

39. DANG X, Zhao W, Li C, Yang H, et al
    Impact of COL6A4P2 gene polymorphisms on the risk of lung cancer: A case-control study.
    PLoS One. 2021;16:e0252082.
    PubMed         Abstract available
    
    
40. ALLEN KL, Cann J, Zhao W, Peterson N, et al
    Correction: Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non-small-cell lung carcinoma and rodent tumor models.
    PLoS One. 2021;16:e0252060.
    PubMed         Abstract available
    
    
41. GOFFIN JR, Corriveau S, Tang GH, Pond GR, et al
    Management and outcomes of patients with chronic obstructive lung disease and lung cancer in a public healthcare system.
    PLoS One. 2021;16:e0251886.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: